Lillia Logo

Stories of change

Lillia is transforming chronic disease management. With AI precision and human empathy, we empower people to take control of their health—one micro-change at a time.

Elderly man holding hands with a doctor, smiling warmly.

Mr. Ar*****: Reversing diabetes naturally

"From HbA1c 12.6% to 5.7% in 3 months – without allopathic medicines!"

Struggling with uncontrolled diabetes, weight gain, and chronic pain, Mr. Ar***** turned his life around with Lillia’s tech-powered solutions like continuous glucose monitoring. He shed 9 kg and resolved lethargy and skin allergies, proving the power of personalized, non-invasive care.

Client speak

Mohammed Salem, Chief Business Officer, QLM Life and Medical Insurance, Qatar, sharing his experience with Lillia Care

“We are thrilled to collaborate with Lillia in our mission to lower diabetes rates and reduce healthcare costs for over 15,000 QLM members managing the condition. As we advance toward our vision of transforming healthcare from ‘Illness to Wellness,’ we eagerly anticipate the innovative AI-driven health solutions and systems they are developing.”

Mohammed Salem,

Chief Business Officer, QLM Life and Medical Insurance, Qatar

Best-in-class clinical impact

PHCC, Qatar: Largest diabetes management study in GCC

Published by American Diabetes Association (ADA) Cohort of 633 patients across 27 Primary Health Care Corporation (PHCC) clinics


Outcome highlights

  • Reduction in HbA1c:
    0.91% reduction for patients with initial HbA1c ≥ 8
  • Reduction in blood pressure:
    7.84% reduction in systolic blood pressure for patients with initial BP ≥ 130/80
  • Reduction in cholesterol:
    0.81 mmol/L reduction in total cholesterol for patients with cholesterol levels ≥ 5.18 mmol/L
  • Reduction in weight:
    0.72% reduction in BMI for patients with initial BMI ≥ 25

India: Large-scale diabetes management study

Published by American Diabetes Association (ADA) Cohort of 808 patients across 50 cities in India


Outcome highlights

  • Reduction in HbA1c:
    1.10% reduction for 808 patients
  • Reduction in HbA1c (uncontrolled diabetes):
    2.18% reduction for patients with initial HbA1c ≥ 9
  • Increase in time in range (TIR):
    7.16% increase for patients with initial TIR of 40.3% ± 31%

Case Study: Leading clinic chain in India

Obesity and Diabetes Management Program


Outcome highlights

  • Reduction in HbA1c:
    1.40% average reduction
  • Reduction in BMI:
    3.35 average reduction for most compliant users
  • Reduction in weight:
    3.50kg average reduction